TY - JOUR
T1 - Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line
T2 - a retrospective multinational study
AU - Almeida, António M.
AU - Prebet, Thomas
AU - Itzykson, Raphael
AU - Ramos, Fernando
AU - Al-Ali, Haifa
AU - Shammo, Jamile
AU - Pinto, Ricardo
AU - Maurillo, Luca
AU - Wetzel, Jaime
AU - Musto, Pellegrino
AU - Van De Loosdrecht, Arjan A.
AU - Costa, Maria Joao
AU - Esteves, Susana
AU - Burgstaller, Sonja
AU - Stauder, Reinhard
AU - Autzinger, Eva M.
AU - Lang, Alois
AU - Krippl, Peter
AU - Geissler, Dietmar
AU - Falantes, Jose Francisco
AU - Pedro, Carmen
AU - Bargay, Joan
AU - Deben, Guillermo
AU - Garrido, Ana
AU - Bonanad, Santiago
AU - Diez-Campelo, Maria
AU - Thepot, Sylvain
AU - Ades, Lionel
AU - Sperr, Wolfgang R.
AU - Valent, Peter
AU - Fenaux, Pierre
AU - Sekeres, Mikkael A.
AU - Greil, Richard
AU - Pleyer, Lisa
PY - 2017/4/14
Y1 - 2017/4/14
N2 - Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. Themedian survival ranges between 3-9months frominitial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.
AB - Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. Themedian survival ranges between 3-9months frominitial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.
KW - Acute erythroleukemia
KW - Azacitidine
KW - Decitabine
UR - http://www.scopus.com/inward/record.url?scp=85018470782&partnerID=8YFLogxK
U2 - 10.3390/ijms18040837
DO - 10.3390/ijms18040837
M3 - Article
C2 - 28420120
AN - SCOPUS:85018470782
SN - 1661-6596
VL - 18
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 4
M1 - 837
ER -
